Abstract:[Objective] To study the efficacy and safety of donepezil in the treatment of patients with mild tomoderate Alzheimer's disease (AD) in our country. Methods: 48 cases with mild to moderate AD were divided intotwo groups randomly and treated bydonepezil and rivastigmine, respectively. Mini Mental State Examination (MMSE),Blessed-Routh Rating Scale BRRS) and Global Deterioration Scale (GDS) were evaluated for efficacy, Vital signs,ECG and laboratorial tests were measured every 4 weeks for safety. Results: The scores of MMSE, GDS and BRRSin the two groups were improved greatly (P＜0.05). But the difference of those scores between two groups at bothbaseline and end-point was not ignificant P＞5). Gastrointestinal reaction as adverse event occurred in 13.6%～29.5% patients in two groups and more commonly in rivastigmine treatment. Conclusion: Donepezil and rivastigmineboth similarly improve cognitive ability, dementia degree and daily living ability in AD patients in our country andhave generally well toleration and safety.

Clinical study of donepezil in treatment of patients with mild to moderate Alzheimer's disease